24
Mar

Investigators for Novartis pumped out more positive Phase III data for its psoriasis therapy secukinumab over the weekend, adding some patient satisfaction scores on the self-injected treatment as the company positions this new product against a host of rivals that promise to quickly crowd the field.

…read more

Source: Eyeing rival mAb mob, Novartis touts PhIII secukinumab psoriasis data

    

0 No comments